FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* HO WILLIAM  (Last) (First) (Middle) C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE  (Street) SOUTH SAN FRANCISCO CA 94080						2. Issuer Name and Ticker or Trading Symbol RAPT Therapeutics, Inc. [ RAPT ]  3. Date of Earliest Transaction (Month/Day/Year)  11/16/2020  4. If Amendment, Date of Original Filed (Month/Day/Year)										S. Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director 10% Owner     X Officer (give title Other (specify below)     Chief Medical Officer      6. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																		
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
Da					2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.			4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			5, 4 and Securition Benefici Owned I		es ally Following	Form (D) o	n: Direct c r Indirect E estr. 4)	7. Nature of Indirect Beneficial Ownership	
										Code	,	Amount	(A) or (D)		Price	Reporte Transac (Instr. 3	tion(s)			Instr. 4)	
Common	Stock	11/16	/2020	)				M		3,356	5 1	1	\$6.18	3 67	67,414		D				
Common Stock 11/16							2020			M		5,000	) /	1	\$6.3		2,414		D		
Common Stock 11/16/						2020				S <sup>(1)</sup>		1,000	) ]	\$20.2		5 71	71,414		D		
		Т	able II -									osed of, onverti				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemo Execution if any (Month/Da	Date,	4. Transaction Code (Instr 8)				6. Date Exercisa Expiration Date (Month/Day/Year				7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly [C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	٧	(A)	(D)	Date Exe	e ercisable		xpiration ate	Title	or Nu of	umber						
Option (right to buy)	\$6.18	11/16/2020			М			3,356		(2)	0.3	3/27/2028	Commo Stock	n 3	,356	\$0	4,861		D		
Option (right to	\$6.3	11/16/2020			M			5,000		(2)	03	3/27/2029	Commo	n 5	,000	\$ <del>0</del>	11,666		D		

## **Explanation of Responses:**

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
- 2. Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following

## Remarks:

/s/ Karen C. Lam, Attorney-in-Fact for William Ho

\*\* Signature of Reporting Person

11/18/2020

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.